Covidien’s Cole Lannum talks about IR around a spin-off and dialing back IR after busy times

May 02, 2014
<p>Video interview from the red carpet at the IR Magazine Awards -&nbsp;US 2014</p>

Covidien, a medical device company with a market cap of around $32 bn, was voted number one for best overall investor relations four years in a row by analysts and investors surveyed for the IR Magazine Awards – US. 

In this red carpet interview at the gala awards event in New York on March 26, 2014, vice president of IR Cole Lannum gives the IR team’s perspective on the successful spin-off of Covidien’s Mallinckrodt pharmaceuticals business in July 2013. 

Lannum describes how Covidien, with the Mallinckrodt spin-off behind it, and after several years of frenetic IR activity since it spun off from Tyco International in 2006, is beginning to dial back its investor marketing. It may be possible to spend too much time on IR, even in shareholders’ eyes, he suggests. 

Finally, Lannum talks about the strong IR credo of Covidien’s top management, including José Almeida, who won best IR by a CEO (large cap), and CFO Charles Dockendorff, who is retiring at the end of 2014. 

Sign up to get stories direct to your inbox
logo-black logo-black